SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending downwards, with community members debating potential support levels and the impact of a possible rate hike from the Bank of Japan. Some traders are anticipating a bounce, while others believe the price will continue to decline, potentially triggering liquidations and further market corrections. Sentiment seems mixed as participants assess both technical indicators and broader macroeconomic factors.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry ($BB.TSX) is trending as investors analyze the potential impact of upcoming earnings and partnerships, especially regarding QNX technology. Bullish sentiment is fueled by optimism around QNX's expanding role in automotive and IoT, with community members closely watching technical indicators and revenue potential. Discussions also involve institutional investment trends and potential market catalysts.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is trending as traders discuss the potential for a rebound amid fluctuating weather forecasts and debate whether natural gas prices are already reflecting winter demand; the community is actively analyzing technical indicators and storage data, while considering factors like LNG exports and production levels to gauge future price movements.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF ($BTC) is trending as the crypto market experiences volatility, with community members debating potential support levels and future price movements. Some traders are eyeing opportunities in options, while others express concerns about market liquidity and potential pullbacks. Broader discussions include the impact of macro factors like interest rates and potential regulatory developments in the crypto space.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

FRMI is experiencing significant volatility as investors debate its future as an energy provider for data centers, particularly after a canceled funding agreement; the stock saw a sharp decline but is now recovering. Community discussion centers on political connections, potential new tenants (including speculation around big tech partnerships), and the company's ambitious plans in the Texas energy market. Despite some skepticism about its current financials, the stock continues to generate buzz due to its unique position and the growing demand for AI infrastructure.

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Immunome Inc

Immunome ($IMNM) is trending amid discussions surrounding topline results from their Phase 3 RINGSIDE trial for desmoid tumors, expected soon, and a recent analyst upgrade. While some investors express nervousness about the lack of previously discussed progression-free survival (PFS) data, the community is actively debating the potential for a significant stock pop based on trial outcomes. Bullish investors point to high-end salaried job postings as a sign of confidence in the pipeline.

Equinox Gold Corp. is a growth-focused mining company, which engages in the exploration of gold mining properties. It operates through the following segments: Greenstone, Mesquite, Castle Mountain, Los Filos, Aurizona, Fazenda, RDM, Santa Luz, and Corporate. The company was founded by Marc Pais on March 23, 2007, and is headquartered in Vancouver, Canada.

Equinox Gold Corp

Equinox Gold is trending due to the announcement of selling its Brazil operations for over $1 billion, a move aimed at focusing on North American growth and generating significant upfront cash. The community is discussing the potential upside from this strategic shift, especially with the price of gold holding strong, and some are noting large call option purchases signaling bullish sentiment. Some analysts have also raised their price targets, adding to the positive momentum.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as investors digest economic data and speculate on the Fed's next moves, particularly regarding rate cuts and a potential shift in leadership. Community discussions revolve around the impact of these factors on bond yields and the broader market, with some expressing concerns about inflation and the strength of the economic recovery. The ETF's performance is also influenced by global factors like the Bank of Japan's policy and trade dynamics.

Anheuser-Busch InBev SA/NV operates as a holding company, which engages in the manufacture and distribution of alcoholic and non-alcoholic beverages. It operates through the following geographical segments: North America, Middle Americas, South America, EMEA, Asia Pacific, and Global Export and Holding Companies. The company was founded on August 2, 1977 and is headquartered in Leuven, Belgium.

Anheuser-Busch InBev SA/NV - ADR

Anheuser-Busch InBev

Recent acquisitions, potential partnerships with cannabis companies, and digital transformations are driving conversation around $BUD, with some investors seeing it as undervalued. However, debate continues around the company's prior marketing decisions and their impact on market share, as well as broader trends in alcohol consumption and consumer preferences. Some analysts are downgrading the stock, while others are maintaining a positive outlook.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

Bitwise XRP ETF is trending as the community discusses its potential impact and recent performance, including comparisons to other crypto ETFs. Discussions range from technical analysis and market predictions to the broader implications of institutional investment in XRP and its role in bridging traditional finance with cryptocurrency. Some traders are pointing to volume as a key factor for a potential turnaround.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Cuban reportedly said that he was talking to Humana about “putting together direct-to-employer programs”.</li><li>Cuban sells mail-order medications directly to customers through Cost Plus Drugs company by removing middlemen such as pharmacy benefit managers.</li><li>Humana, meanwhile, is expanding its pharmacy business.</li></ul>Health insurance company Humana (HUM) is reportedly working with billionaire Mark Cuban on a potential pharmacy partnership.The announcement was made by Cuban and Humana CEO at the Forbes health care conference, Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-12-04/humana-working-with-mark-cuban-on-potential-pharmacy-partnership?srnd=homepage-asia">reported</a>. While the announcement was light on details, the move would step up pressure on larger pharmacy middlemen, the report noted.<h2 class="st-heading-2">Cuban, Humana Talk About Partnership</h2>Cuban reportedly said that he was talking to Humana about “putting together direct-to-employer programs”. Humana CEO Jim Rechtin also highlighted that he is looking to simplify the process of getting drugs from manufacturers to patients, Bloomberg reported.Cuban sells mail-order medications directly to customers through Cost Plus Drugs company by removing middlemen such as pharmacy benefit managers. The billionaire is critical of pharmacy benefit managers. Last month, the billionaire blamed PBMs for hiking the prices of GLP-1 drugs used for weight loss and as a treatment for diabetes.Pharmacy benefit managers (PBMs) are third-party administrators that act as intermediaries between health insurance plans, pharmacies, and drug manufacturers to manage prescription drug benefits.<h2 class="st-heading-2">Humana’s Pharmacy Business</h2>Humana, meanwhile, is expanding its pharmacy business. It offers pharmacy under its CenterWell business division which also includes senior-focused primary care and home health services. In November, the company said that it witnessed continued strong CenterWell pharmacy growth with increased specialty volumes and strong direct to consumer growth, both exceeding previous expectations in 3Q25.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>HUM shares traded closed down about 2% on Thursday. On Stocktwits, retail sentiment around HUM stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<a href="https://stocktwits.com/symbol/HUM">HUM stock</a> is down marginally this year and by about 12% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pepsico-close-to-striking-settlement-with-activist-giant-elliott-after-4-billion-push-for-change/cLIi4iXREj1">PepsiCo Is Close To Striking A Settlement With Activist Giant Elliott After Its $4B Push For Change</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

The MyHumana app page is displayed on a smartphone in the Apple App Store in front of the Humana Inc logo on October 30, 2024 in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Billionaire Mark Cuban And Humana Tease A New Pharmacy Deal Aimed At Cutting Out Middlemen: Report

The announcement was made by Cuban and Humana CEO at the Forbes health care conference, Bloomberg reported.

Equity

The announcement was made by Cuban and Humana CEO at the Forbes health care conference, Bloomberg reported.


<ul class="summary-bullets"><li>Moderna said that the five-year term loan facility will strengthen its balance sheet and provide increased flexibility going forward.&nbsp;</li><li>The company continues to target cash breakeven by 2028 and to reduce its expected cash costs for 2026 and 2027.</li><li>It will build a vaccine franchise with as many as six approved products by 2028 and invest cash generated to diversify its portfolio. &nbsp;</li></ul>Vaccine maker Moderna (MRNA) said on Thursday that it has secured a $1.5 billion, five-year credit facility from Ares Management Credit Funds as it seeks to pivot into oncology and rare-disease therapeutics.The company is now eyeing 10% revenue growth in 2026. It said that the five-year term loan facility will strengthen its balance sheet and provide increased flexibility going forward.The initial tranche of $600 million, of three tranches, will be drawn upfront, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=9002529460187539&amp;symbol=MRNA">said</a>, followed by the option to avail $400 million through November 2027. The company can also draw another $500 million through November 2028 under the credit facility contingent on the achievement of key regulatory milestones.<h2 class="st-heading-2">Moderna’s Near-Term Goals</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=5758345706655596&amp;symbol=MRNA">continues</a> to target cash breakeven by 2028 and reduce its 2026 and 2027 expected cash costs with cost management and by prioritizing certain research and development efforts.Moderna rose to fame during the COVID-19 pandemic with its mRNA-based vaccine Spikevax. In the third quarter of 2025, the company reported total revenue of $1 billion, down from $1.9 billion in the corresponding period of 2024, mainly due to lower COVID-19 vaccine sales. However, Covid vaccine sales accounted for a whopping 97% of the company’s overall revenue in the three months through the end of September."Over the next three years, we expect to build a large seasonal vaccine franchise for at-risk populations and invest the cash generated into oncology and rare disease therapeutics," CEO Stéphane Bancel said on Thursday.The company will build a vaccine franchise with as many as six approved products by 2028 and invest cash generated from its portfolio, including Spikevax, mRESVIA and mNEXSPIKE, as well as other yet-to-launch vaccines, including a flu-covid combination vaccine, into diversifying its portfolio.Investment in late-stage oncology and rare disease programs will set the company up for additional growth in 2027 and 2028, the company said.Moderna’s pipeline currently consists of two oncology therapies and two rare disease therapeutics that are under development. It discontinued four programs, including those for congenital Cytomegalovirus, herpes simplex virus, Varicella-Zoster virus and Glycogen Storage Disease Type 1a (GSD1a) as part of its efforts to prioritize some research investments.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> remained in the ‘bearish’ territory, while message volume dropped from ‘low’ to ‘extremely low’.MRNA stock is down by 42% this year and by 35% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pacs-group-stock-soars-premarket-on-completion-of-audit-commitee-probe-upbeat-full-year-guidance/cLPAjZFREa9">PACS Group Stock Soars Premarket On Completion Of Audit Committee Probe, Upbeat Full-Year Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna Secures $1.5B Credit Facility As It Seeks To Pivot Away From Vaccines

The company is now eyeing 10% revenue growth in 2026.

Philip Morris International Inc. (PM) said on Wednesday that its experts met with the Tobacco Products Scientific Advisory Committee on October 7 as it seeks to continue marketing versions of its IQOS heated tobacco products in the U.S. as modified risk tobacco products.The committee provides nonbinding recommendations to the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP). The modified risk tobacco product designation granted by the FDA initially in 2020 allowed the company to advertise its perks, including that the IQOS system heats tobacco instead of burning it, significantly reducing the production of and users’ exposure to harmful chemicals.PMI has requested that it be allowed to continue marketing versions of IQOS as modified risk tobacco products.“We encourage the FDA to continue efforts to establish a timely scientific review process for smoke-free products—including for IQOS ILUMA, which has been pending FDA review for nearly two years and has globally shown even higher rates of legal-age adults fully switching from combustible cigarettes—that are a better choice for legal-age adults who would otherwise use traditional tobacco products, including combustible cigarettes,” PMI U.S. CEO Stacey Kennedy <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251008608945/en/Philip-Morris-International-Urges-U.S.-Food-and-Drug-Administration-Advisory-Committee-to-Recommend-Continued-Marketing-of-IQOS-as-Modified-Risk-Product">said</a>.The company estimates that there are approximately 34 million IQOS consumers globally who have moved away from cigarettes or significantly reduced their consumption as of June 30. PMI first entered the U.S. market in 2022, following its acquisition of Swedish Match.On Stocktwits, retail sentiment around PM stock fell from 'extremely bullish' to 'bullish' territory over the past 24 hours, while message volume stayed at 'high' levels.&nbsp;<a href="https://stocktwits.com/symbol/PM">PM stock</a> is up by 28% this year and by 30% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ford-faces-1-billion-hit-after-new-york-aluminum-plant-fire-analysts-say/ch6EZaVR3iF">Ford Faces Up To $1 Billion Hit After New York Aluminum Plant Fire, Analysts Reportedly Say</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Philip Morris International Inc. is displayed on a smartphone screen, with the company's branding in the background, on April 20, 2025, in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Philip Morris Seeks FDA Approval To Keep IQOS Modified Risk Designation For Later Versions Of Device

The modified risk tobacco product designation granted by the FDA initially in 2020 allowed the company to advertise IQOS’ perks. 

Shares of CarMax (KMX) slumped 24% on Thursday morning after the company’s second-quarter earnings fell below Wall Street expectations, sparking a downgrade by Wedbush.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://media.carmax.com/press-releases/news-release/2025/CarMax-Reports-Second-Quarter-Fiscal-Year-2026-Results/default.aspx">Total vehicle sales</a> for the company declined 4.1% year-over-year in the quarter to 338,031 units, resulting in a 6% decrease in revenue to $6.59 billion, which fell short of the estimated $7.02 billion. Net earnings per share came in at $0.64, down from $0.85 in the corresponding quarter of 2024.Total net income declined 28% to $95.4 million, while income from the company’s auto finance business fell 11.2% to $102.6 million. The company pinned the drop in income from the auto finance segment to an increase in the provision for loan losses, which outweighed growth in net interest margin.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KMX">KMX stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.CEO Bill Nash admitted that the quarter was “challenging,” but said the used auto retailer remains confident in its long-term strategy. Wedbush subsequently downgraded CarMax to ‘Neutral’ from ‘Outperform’ and revised the price target to $54, down from $84.The new price target implies a downside of about 5% from the stock’s closing price on Wednesday.The "weak results" in Q2 underperformed expectations across "all key metrics," Wedbush said. &nbsp;These results are amplifying investors' concerns around management's ability to sustain market leadership and drive additional growth, according to the analyst. Wedbush is now eyeing a potential revision of its estimates for the company following the earnings call.KMX stock is down 46% this year and approximately 41% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-more-than-doubles-on-thursday/chDla07R34F">PepGen Stock More Than Doubles On Thursday – Check Out The New Price Targets On Wall Street</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A view of a CarMax dealership on April 10, 2025 in Santa Rosa, California. (Photo by Justin Sullivan/Getty Images)

Why Did CarMax Stock Tumble 24% Today?

Total vehicle sales of the company fell 4.1% year-over-year in the second quarter to 338,031 units, dragging revenue by 6% to $6.59 billion.

Bristol Myers Squibb (BMY) announced on Thursday that it will sell its moderate-to-severe plaque psoriasis drug, Sotyktu, at a discount of more than 80% to the current list price, starting in January 2026, to cash-paying patients.Patients can purchase the drug at a discount on the company’s BMS Patient Connect direct-to-patient platform. Eligible cash-paying U.S. patients with a Sotyktu prescription can buy the medicine through the platform, which offers shipping across all 50 states and Puerto Rico, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Builds-on-Eliquis-apixaban-Direct-to-Patient-Program-Announces-New-BMS-Patient-Connect-Platform-Offering-Sotyktu-deucravacitinib/default.aspx">stated</a>. The platform will also provide patient support resources, it added.“We are taking a leading role in removing barriers, providing transparency and lowering out-of-pocket costs so patients in the United States can get the treatments they need – delivered directly to their door, wherever they are in the country,” CEO Christopher Boerner said.The announcement comes on the heels of President Trump <a href="https://stocktwits.com/news-articles/markets/equity/trump-to-issue-60-day-warning-letters-to-drugmakers-over-pricing/choL0IMRdGB">sending</a> letters to 17 drugmakers demanding that they lower drug prices in the U.S. to levels paid by other wealthy nations. The deadline for meeting the demand is on Monday, and the White House has warned of action against those who do not comply.Shares of the company traded 0.3% higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BMY">BMY stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.In July, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://google.com/url?q=https://stocktwits.com/news-articles/markets/equity/bristol-myers-pfizer-to-offer-blood-thinning-drug-at-discount/ch8K8XqR5pI&amp;sa=D&amp;source=docs&amp;ust=1758807238695403&amp;usg=AOvVaw1vujNK93MaBpbwKU9R5Fiv">announced</a> that it will sell its blood thinner drug Eliquis to cash-paying patients for more than 40% discount to the current list price. Eliquis is a prescription medicine used in adults to reduce the risk of stroke and blood clots in people who have atrial fibrillation (AFib), a type of irregular heartbeat, not caused by a heart valve problem. It is also used to treat blood clots in the veins of the legs or lungs, and reduce the risk of them occurring again after receiving treatment for blood clots.BMY stock is down approximately 22% this year and by about 12% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-rises-pre-market-over-fresh-hopes-of-deramiocel-approval-in-treating-genetic-disorder/chDlIyZR34h">Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Bristol-Myers Squibb Company logo is seen displayed on a tablet. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026

Patients can purchase the drug at a discount on the company’s BMS Patient Connect direct-to-patient platform.

Shares of DexCom (DXCM) declined 10% on Friday after investment firm Hunterbrook Capital disclosed a short position in the stock.Hunterbrook <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://hntrbrk.com/dexcom/">said</a> on Thursday that it has a short position on DXCM based on Hunterbrook Media’s reporting, which stated that after inaccurate readings from Dexcom’s flagship G7 continuous glucose monitor (CGM) device, “some diabetics are ending up in the ICU — or dead.” Hunterbrook Media is an investigative news outlet.The report stated that DexCom made an unauthorized design change to a key component of the G7 that internal studies showed was inferior by “every accuracy metric,” and the company sold the device anyway. This change was revealed during a surprise inspection by the U.S. Food and Drug Administration (FDA), the report stated.Several company executives left the company amid the FDA’s scrutiny and soaring complaints, the report said, while adding that patients are now returning to the G6 or switching to products from competitors, such as Abbott (ABT).Hunterbrook also stated that it has shared its probe with a senior official from the Health and Human Services (HHS) and requested that the FDA intervene. The firm also said that DexCom didn't respond to their requests for comments. The report named people who died or had to be hospitalized following wrong readings by the G7 device, including Billy Sosbe, who died in June, and Diana Bates Knight, who rushed her 6-year-old to the emergency, after the device misread her blood sugar by hundreds of points.“In Dexcom’s crisis, Abbott may see its chance. Our analysis of FDA data shows Dexcom receives more accuracy complaints than its market share predicts; Abbott receives significantly fewer,” Hunterbrook said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DXCM">DXCM</a> rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:578/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_2_14_55_PM_png_eb2477f011.webp" alt="DXCM's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="578" height="57"><figcaption>DXCM's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that DexCom has proven technology and is leading in CGM.<stembedurl>https://stocktwits.com/CmonManGiveMeABreak/message/629329227</stembedurl>Another user, however, opined that the FDA might pull the G7 device from the market.<stembedurl>https://stocktwits.com/buddyopalosam/message/629325830</stembedurl>DXCM stock is down by 13% this year and by 5% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/equity/markets/kalvista-pharmaceuticals-hereditary-angioedema-drug-approved-in-eu-switzerland/chD3BkIR3TW">KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the DexCom logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

DexCom Stock Slumps 10% After Hunterbrook Media Investigation Raises Concerns About Its G7 Device

Hunterbrook Capital said on Thursday that it has a short position in DXCM stock based on Hunterbrook Media’s reporting, which stated that some diabetics died after inaccurate readings from Dexcom’s G7  device.

Hunterbrook Capital said on Thursday that it has a short position in DXCM stock based on Hunterbrook Media’s reporting, which stated that after inaccurate readings from Dexcom’s G7 continuous glucose monitor device, some diabetics are ending up in the ICU or dead.


Shares of GE Healthcare Technologies (GEHC) jumped 1% in the pre-market session on Thursday, following reports that the company is considering options, including the sale of a stake in its China unit.Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-18/ge-healthcare-is-said-to-explore-selling-stake-in-china-business?srnd=homepage-asia">reported</a> on Thursday, citing people familiar with the matter, that the U.S.medical technology company has been working with advisers to evaluate options for the business. A potential transaction may value the China assets at several billion dollars, the report said.However, no final decision has been made on the timing and size of a potential disposal, and considerations are preliminary, sources told Bloomberg. According to the report, China is the company’s second-largest market, with approximately 7,000 employees in the region. &nbsp;On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GEHC">GEHC stock</a> fell from ‘bullish’ to’ neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:928/100;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_18_083008_png_caa300d3aa.webp" alt="GEHC's Sentiment Meter and Message Volume as of 7:49 a.m. ET on Sept. 18, 2025 | Source: Stocktwits" width="928" height="100"><figcaption>GEHC's Sentiment Meter and Message Volume as of 7:49 a.m. ET on Sept. 18, 2025 | Source: Stocktwits</figcaption></figure>GE Healthcare was spun off from General Electric in 2023. It delivers advanced technologies, pharmaceutical diagnostics, and AI-powered tools for medical use. According to the company, it has over 200 imaging software applications and treats over a billion patients annually.In February, the company said that its revenue growth in the U.S. in 2024 was partially offset by continued market softness in China. For the second quarter, GE Healthcare reported adjusted earnings per share of $1.06, compared to $1 in the corresponding quarter of 2024, and revenue growth of 3% on a reported basis to $5 billion.GEHC stock is down 2% this year and approximately 13% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-89bio-stock-nearly-double-in-value/chDcHJIR3bc">Why Did 89bio Stock Nearly Double In Value Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of GE HealthCare Technologies Inc. in front of a screen showing the company's latest stock market chart on July 28, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GE Healthcare Reportedly Eyes Selling Stake In China Unit – More Details Inside

According to a Bloomberg report, no final decision has been made on the timing and size of a potential disposal, and considerations are preliminary.

Regeneron Pharmaceuticals, Inc. (REGN) said on Monday that its experimental therapy significantly reduced symptoms of cat and birch allergies in late-stage trials, successfully meeting their key endpoints.In the <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.regeneron.com/news-releases/news-release-details/regeneron-advances-allergy-pipeline-two-positive-phase-3-trials">trials</a>, patients with moderate to severe cat or birch allergies received direct instillation of either cat dander or birch pollen into the eyes, followed by a single subcutaneous administration of the allergen-blocking antibodies. The antibody blockers “significantly reduced” allergy symptoms compared to placebo, the company said.The company stated that the data from the studies will be presented at an upcoming medical conference and used to inform confirmatory late-stage trials. Both the cat and birch allergy programs are part of a broader allergy pipeline, which includes an ongoing study in adults with severe food allergy. Initial results from the food allergy trial have been encouraging, the company said on Monday.Regeneron Chief Scientific Officer George D. Yancopoulos stated on Monday that the company anticipates significant relief at the earliest assessment time point, which is expected to last over three months, in both our cat and birch allergy programs.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REGN">REGN stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels. Shares of the company traded 1% higher in the pre-market session at the time of writing.Yancopoulos said that while millions suffer from the effects of allergies, most undergo allergy desensitization shots, often with disappointing results.“The purpose of these burdensome allergy shots is to try to build up allergen-blocking antibodies in the body. We wondered whether we could instead manufacture and directly provide allergen-blocking antibodies,” he said. “These recent Phase 3 allergen challenge trials, together with our earlier Phase 2 trials, provide compelling evidence that our first-in-class approach can have the potential to provide profound allergy relief – rapidly and durably after a single treatment – decreasing ocular, nasal and even asthma measures.”Regeneron noted that Birch pollen is one of the most common seasonal allergens in the U.S., affecting more than 10 million people, while cat allergy affects more than 20 million people. In the trials, patients received a combination of two antibody blockers or a placebo. Those who received the combination had fewer allergy symptoms, such as conjunctival redness.While additional late-stage trials in cat allergy are planned to begin in the first half of 2026, further late-stage development in birch allergy is expected to commence by the end of the year.REGN stock is down by 20% this year and by about 50% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/echostar-to-dell-17-billion-in-spectrum-assets-to-spacex/chwWH3JRdAD">EchoStar To Sell $17B In Spectrum Assets To SpaceX – Stock Rockets 40% Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Get updates to this developing story <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-experimental-therapy-reduced-symptoms-of-cat-birch-allergies-in-studies/chwWH37RdAw">directly on Stocktwits.</a>

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Regeneron Says Experimental Therapy Reduced Symptoms Of Cat, Birch Allergies In Late-Stage Trials

The company said that the antibody blockers “significantly reduced” allergy symptoms compared to a placebo in the trials. 

Regeneron Pharmaceuticals, Inc. (REGN) announced on Tuesday that the late-stage trial evaluating its investigational Cemdisiran monotherapy in adults with generalized myasthenia gravis (MG) yielded positive results.MG is a rare and chronic autoimmune disease where disrupted communication between nerves and muscles results in debilitating and potentially life-threatening muscle weakness. According to Regeneron, the disease impacts approximately 85,000 people in the U.S.Both Cemdisiran and the combination of Cemdisiran and the approved antibody Pozelimab (cemdi-poze) demonstrated improvements in activities of daily functioning such as talking, eating, breathing, vision, and mobility at week 24. Cemdisiran showed numerically better results across all generalized myasthenia gravis-specific outcomes, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-announces-positive-results-phase-3-trial-generalized">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REGN">REGN stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels. Shares of the company traded 2% higher at the time of writing.<figure class="image"><img style="aspect-ratio:576/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_26_at_12_07_06_PM_png_ed2effdb15.webp" alt="REGN's Sentiment Meter and Message Volume as of 12:07 p.m. ET on Aug. 26, 2025 | Source: Stocktwits" width="576" height="61"><figcaption>REGN's Sentiment Meter and Message Volume as of 12:07 p.m. ET on Aug. 26, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user believes that the stock may hit an all-time low soon.<stembedurl>https://stocktwits.com/Johny34211/message/626531477</stembedurl>The firm said that treatment-emergent adverse events (TEAEs) occurred in 69% of patients treated with Cemdisiran, 81% with cemdi-poze, and 77% with placebo. Serious TEAEs occurred in 3% of patients treated with Cemdisiran, 9% with cemdi-poze, and 14% with placebo, the company said. However, there were no treatment discontinuations due to adverse events through week 24 in the Cemdisiran arm, it added.The company also said that there were no deaths during the 24-week placebo-controlled portion of the trial. During the extension period, however, one death due to pneumonia occurred in the Cemdisiran arm, and one death due to septic shock occurred in the combination arm. Both deaths occurred in patients who were on concomitant immunosuppressive therapies, Regeneron said.The company now plans to apply for regulatory approval in the U.S. for Cemdisiran in the first quarter of 2026, pending discussions with the U.S. Food and Drug Administration (FDA).REGN stock is down by 18% this year and by 51% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-upgraded-nio-shares-with-price-target-hike/chsHCIGRdjA">This Chinese EV Stock Surged 8% Today And JPMorgan Just Upgraded The Shares With A Price Target Hike: Retail Eyes $10 By End Of Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Regeneron Stock Rallies After Therapy For Autoimmune Disease Meets Late-Stage Trial Goals: Retail Thinks Stock Might Hit An All-Time Low Soon

The company now plans to apply for regulatory approval in the U.S. for Cemdisiran in the first quarter of 2026, pending discussions with the FDA.

Regeneron Pharmaceuticals, Inc. (REGN) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has extended the date by which it is expected to rule on two of its EYLEA HD Injection regulatory submissions.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://newsroom.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-injection-8-mg-applications-expanded-us">said</a> that the FDA will now decide on its submissions by the fourth quarter of 2025. The agency extended review time after determining that information provided since the completion of a recent inspection of a third-party manufacturer constituted a major amendment to each submission. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REGN">REGN</a> remained within the ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.Regeneron had submitted applications pertaining to the EYLEA HD prefilled syringe and another seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week dosing across approved indications. The delay, however, was <a href="https://stocktwits.com/news-articles/markets/equity/truist-cuts-price-target-on-regeneron-citing-near-term-investor-focus-on-eylea/chrHEcxRdeF">anticipated</a>, the company said.The firm said it resulted from observations during an FDA general site inspection at Catalent Indiana LLC, &nbsp;the filler for these regulatory applications.Novo Nordisk recently acquired Catalent. The firm submitted a response earlier this month to address the observations noted by the FDA. Regeneron said that the FDA will be able to act on its applications once the manufacturing issues are resolved. The FDA was previously expected to decide on the submissions by August 2025.EYLEA HD, however, remains available in the U.S. through vial administration and is approved to treat vision-threatening conditions that impact patients, such as wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR).REGN stock is down by 17% this year and by about 51% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-says-tesla-model-yl-might-not-ever-come-to-us-markets/chsitLlRdhq">Elon Musk Said Tesla’s Model Y L Might Not Ever Come To US Markets – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions

The company said that the FDA will now decide on its submissions by the fourth quarter of 2025.

AIEQ
Amplify AI Powered Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Latest AIEQ News

AIEQAmplify AI Powered Equity ETF